Build status - In Progress

NAC Attack A Phase III Multicenter Randomized Parallel Double Masked Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa

Recruiting
99 years or below
All
1 Location

Brief description of study

The objective of the study will be to evaluate the efficacy and safety of oral N-acetylcysteine (NAC) in patients with retinitis pigmentosa (RP). The study is a multi-center, randomized, placebo-controlled study where adult patients diagnosed with RP will be asked to take 1800mg NAC bid or a placebo. Patients will be followed for 45 months with a series of clinic visits, tele-visits and phone calls, and safety and efficacy will be assessed using tests to measure visual function and structure.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 14 Jun 2023. Study ID: 853552

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center